Transcatheter aortic valve replacement (TAVR) is an alternative to surgical aortic valve replacement (SAVR) for patients with symptomatic severe aortic stenosis who are at high risk of perioperative mortality. Previous studies showed increased risk of postoperative AKI with TAVR, but it is unclear whether differences in patient risk profiles confounded the results. To conduct a propensity-matched study, we identified all adult patients undergoing isolated aortic valve replacement for aortic stenosis at Mayo Clinic Hospital in Rochester, Minnesota from
The occurrence of AKI after cardiac surgery, particularly aortic valve replacement, results in longer length of hospital stay and increased use of hospital resources 1 and is independently associated with short-and long-term mortality. 2, 3 Despite many attempts to identify effective interventions to prevent postoperative AKI, [4] [5] [6] the incidence of AKI after cardiac surgery is reported to remain as high as 30%. 7, 8 Since the first successful surgical aortic valve replacement (SAVR) in 1960, 9 SAVR has remained the gold standard treatment for symptomatic severe aortic stenosis. 10 However, there is a number of patients with comorbidities who will not undergo SAVR because of a high risk of perioperative mortality. Transcatheter aortic valve replacement (TAVR) has emerged as an alternative option for these high-risk patients. 10, 11 Patients selected for TAVR typically have higher comorbidities, including CKD, which may carry a higher risk for AKI. 12 Because TAVR is a less invasive procedure than SAVR, the hope is that TAVR might provide a lower risk of postoperative AKI. Unfortunately, the evidence for the renal protective effect of TAVR is still unsettled. Indeed, several studies have shown a higher incidence of postoperative AKI among patients who underwent TAVR compared with those who had SAVR. 13, 14 However, these results might be confounded by selection bias, because the patients who underwent TAVR usually had more comorbid conditions, many of which are associated with higher postoperative AKI.
The objective of this propensity-matched study was to assess the risk of AKI in patients who underwent TAVR compared with matched patients who underwent SAVR. We used propensity score matching to ensure comparability and similar risk profiles between the groups. In addition, we report the risk of AKI after TAVR in a large cohort of patients with severe aortic stenosis who required valve replacement.
RESULTS
During the study period, 1586 patients underwent aortic valve replacement for aortic stenosis. Of these patients, 20 who had ESRD or had received dialysis within 14 days before surgery and 3 with no research authorization were excluded. In total, 1563 patients (386 in the TAVR group and 1177 in the SAVR group) were included in the initial cohort before matching (Figure 1 ). In the unmatched cohort, patients with TAVR were significantly older, had a higher Society of Thoracic Surgeons (STS) risk score, had more comorbid conditions, and had more prevalence of previous cardiac surgery; in addition, patients with TAVR had a lower baseline eGFR, ejection fraction, and aortic valve gradient compared with patients with SAVR (Table 1) . Furthermore, there was a significant difference in the rate of all blood product transfusion among patients with TAVR and patients with SAVR. One third of the whole cohort required transfusion. Transfusion rate among patients with TAVR was only 22.5%, whereas 35.6% of patients with SAVR received a transfusion (P,0.001). There was no statistical difference between the two groups for platelet transfusion, and there was a trend toward a higher rate of fresh frozen plasma and cryoprecipitate transfusion among patients with SAVR (P=0.05 and P=0.08, respectively). Patients with TAVR received more red blood cell transfusions compared with patients with SAVR (mean, 2.863.6 versus 2.262.5; P=0.03). The average duration of procedure in TAVR was less than in SAVR (127652 versus 191663; P,0.001).
In the entire cohort, postoperative AKI occurred in 106 (27.5%) patients with TAVR, with 22.0% in stage 1, 1.6% in stage 2, and 3.9% in stage 3. In contrast, postoperative AKI occurred in 224 (19.0%) patients with SAVR, with 17% in stage 1, 1.7% in stage 2, and 0.3% in stage 3 ( Table 2) .
CKD played a significant role as a risk factor for AKI in both TAVR and SAVR cohorts. We also noted a dose-response relationship between the incidence of AKI and progressive stages of CKD (Table 3) . Among patients who developed stage 2 or 3 AKI, urine examination was available in 62% (28 of 45). Among patients with available urine examination, renal Figure 1 . The plot of absolute standard difference before and after propensity score matching. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; AV, aortic valve; BMI, body mass index; CABG, coronary artery bypass graft; CHF, congestive heart failure; CLD, chronic liver disease; CV, cardiovascular; CVD, cerebrovascular disease; EF, ejection fraction; MI, myocardial infarction; MV, mitral valve; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; PVD, peripheral vascular diseases; Surg status, surgical status. tubular epithelium or granular cast was present in 71% (20 of 28), suggesting acute tubular necrosis as the etiology of AKI. Serum eosinophilia was more common in the TAVR than in the SAVR group (4% versus 1%; P,0.001).
In unadjusted analysis, AKI occurrence in the TAVR group was significantly higher than in the SAVR group (relative risk, 1.44; 95% confidence interval [95% CI], 1.18 to 1.76; P,0.001). The TAVR group had higher in-hospital mortality (2.9% versus 0.2%; P,0.001), need for RRT (2.9% versus 0.4%; P,0.001), and major adverse kidney events (4.7% versus 0.7%; P,0.001). The 6-month mortality was 10.7% for the TAVR group and 2.5% for the SAVR group (P,0.001) ( Figure 2A ). In adjusted analysis, there was no significant difference in AKI occurrence rate between TAVR and SAVR groups (adjusted odds ratio, 0.70; 95% CI, 0.48 to 1.01; P=0.06).
Propensity score matching created a matched cohort of 195 patients in each group. In this matched cohort, baseline characteristics and preoperative variables were comparable between the TAVR and SAVR groups (Table 1 ). In the matched cohort, postoperative AKI occurred in 47 (24.1%) patients with TAVR; 20% of these patients were in stage 1, 1.5% were in stage 2, and 2.6% were in stage 3. In the SAVR cohort, AKI occurred in 58 (29.7%) patients, with 27.2% in stage 1, 1.5% in stage 2, and 1% in stage 3. There was no significant difference in postoperative AKI between the TAVR and SAVR groups Table 2 . There were also no significant differences in in-hospital mortality (1.5% versus 1%; P=0.65), need for RRT (1% versus 1%; P.0.99), or major adverse kidney events (2.1% versus 1.5%; P=0.70) between the TAVR and SAVR groups. The mean hospital length of stay in TAVR group was shorter than in SAVR group (6.563.4 versus 8.864.3 days; P,0.001). The 6-month mortality was 6% for the TAVR group and 8.3% for the SAVR group (P=0.51) ( Figure 2B ). Among patients who survived at 6 months after surgery, there were no significant differences in eGFR and the need for chronic RRT at 6 months.
DISCUSSION
Using comprehensive propensity score analysis, we found no significant difference in the incidence of postoperative AKI, severe AKI requiring RRT, major adverse kidney events, in-hospital mortality, or 6-month survival among patients undergoing TAVR versus SAVR. For patients who had a significant number of comorbid conditions, we found no difference in the risk of AKI between TAVR and SAVR. Before matching, we noted that patients with TAVR were significantly older, carried higher STS risk scores, and had more comorbid conditions compared with patients with SAVR.
When only a limited number of confounders was taken into account, such as the STS risk score, previous studies found a significantly higher incidence of AKI among patients who underwent TAVR. 13, 14 We showed that, using a robust propensity score-matched analysis incorporating the STS risk score along with other known AKI risk factors, the higher incidence of postoperative AKI, severe AKI requiring RRT, or major adverse kidney events among patients with TAVR disappears.
Patients undergoing SAVR reported to encounter a higher rate of periprocedural transfusions, and they need cardiopulmonary bypasses, 15, 16 which are both associated with generation of thrombin, inflammatory reaction, and increased postoperative bleeding, all of which can lead to AKI development. 17 During cardiopulmonary bypass surgery, upregulation of adhesion molecules, such as CD11b and CD41, platelet activation, and release of cytotoxic oxygen-derived free radicals, proteases, cytokines, and chemokines can lead to significant inflammatory response. 7 At the time of aortic cannulation, the chance of microscopic and macroscopic embolic events is high. 18 This per se can increase the risk of AKI and after maladaptive repair, lead to CKD. In addition, high risk of hemodynamic instability during SAVR and the effect of hypothermia, nonpulsatile blood flow, and euvolemic hemodilution during open heart surgery on the kidney hemodynamics have been considered risk factors of AKI after SAVR. In a study of patients with cardiopulmonary bypass surgery, investigators suggested that mean arterial pressure .70 mmHg was associated with higher intraoperative creatinine clearance when it was compared with the mean arterial pressure of 50-60 mmHg. 7, 19 Although TAVR is associated with fewer hemodynamic and inflammatory changes, it could still be associated with increased risk of AKI because of contrast exposure, atheroembolic events, and hemodynamic instability when the valve 10 Interestingly, three separate randomized, controlled studies have shown different rates of postoperative AKI. 10, 20, 21 Two of the mentioned trials showed no significant difference in postoperative AKI between the TAVR and SAVR groups. 20, 21 One explanation could be differences in AKI definitions, which can affect the AKI incidence between studies. 8 One study with the standard AKI definition 6 showed a significantly reduced AKI risk in the TAVR group. This suggests a potential benefit of TAVR utilization to reduce AKI risk.
Despite the trend of reduction in postoperative AKI risk in the TAVR group in our study, this effect did not translate to a decrease in severe AKI requiring RRT. Comparable survival within 6 months between the TAVR and SAVR groups was consistent with previous meta-analyses. 16, 22 Because the majority of patients who underwent TAVR have significant comorbid conditions, they could have had a higher risk of mortality and AKI if they would have undergone SAVR, or they could have been considered inoperable. Our analysis highlighted that a minimally invasive and less expensive procedure (i.e., TAVR) is not associated with increased risk of complications that are traditionally related to aortic valve replacement.
There are several limitations to our study. (1) This is a single-center, retrospective study. (2) Although our report is the largest propensity score-matched study in the current literature, our limited sample size could underpower our conclusions. (3) We did not include urine output criterion for AKI diagnosis, because an indwelling urinary catheter was not used to obtain accurate hourly urine output data for a large percentage of patients in our cohort. Therefore, the results of this study ultimately need to be validated in a larger, multicenter prospective study.
Our study also has several strengths. We used a very robust propensity-matching method to compare the outcomes among the two groups while removing the effects of other confounders. In addition, our cohort is the largest cohort published in the literature.
In a large, single-center, propensity-matched study, we found that, among patients who have high risk for AKI, TAVR is not associated with higher incidence of AKI, mortality, or need for RRT compared with SAVR. Considering the high incidence of complications associated with open and on-pump surgical procedures and longer time required for recovery, we conclude that TAVR as a less invasive and expensive procedure is an appropriate alternative for SAVR among high-risk patients.
CONCISE METHODS

Study Population
This is a single-center, retrospective study conducted at a tertiary referral hospital. We studied all adult patients (age $18 years old) who underwent isolated aortic valve replacement for aortic stenosis at Mayo Clinic Hospital in Rochester, Minnesota from January 1, 2008 to June 30, 2014. We excluded patients who had ESRD or received any RRT within 14 days before surgery. This study was approved by the Mayo Clinic Institutional Review Board. The informed consent was waived for patients who already provided research authorization. Patients without research authorization were excluded.
Data Collection
Clinical characteristics, demographic information, and laboratory data were collected using manual and automated retrieval from institutional electronic medical records. The risk of operative mortality was calculated on the basis of patient demographics, preoperative clinical characteristics, and procedures using the STS Adult Cardiac Surgery risk calculator. 11, 23, 24 The eGFR was derived using the Chronic Kidney Disease Epidemiology Collaboration equation. 25 CKD was defined as an eGFR,60 ml/min per 1.73 m 2 . Serum eosinophilia was defined as absolute eosinophil count $500 cells/ml.
Clinical Outcomes
The primary outcome was postoperative AKI. We defined and staged AKI solely on the basis of the serum creatinine criterion of the Kidney Disease Improving Global Outcomes Foundation; AKI was defined as an increase in serum creatinine of $0.3 mg/dl within 48 hours after surgery or a relative increase of $50% from the baseline within 7 days after surgery. The baseline values for serum creatinine were obtained as follows. If outpatient serum creatinine measured between 180 and 7 days before surgery was available, the most recent value was used. Otherwise, the lowest value within the 5 days before surgery was used. Secondary outcomes included in-hospital mortality, need for RRT at any time during hospitalization, composite outcome of major adverse kidney events, and 6-month mortality after surgery. We defined major adverse kidney events as the composite of in-hospital death, use of RRT, and persistence of renal dysfunction (defined by serum creatinine $200% of reference) at hospital discharge. Among patients who survived at 6 months after surgery, we assessed renal function by calculating eGFR at 6 months and the need for chronic dialysis. We imputed an eGFR value of 5 ml/min per 1.73 m 2 at 6 months for any patients who needed chronic dialysis.
Statistical Analyses
All continuous variables were reported as means6SDs. All categorical variables were reported as counts with percentages. For patients with multiple aortic valve replacement surgery, only the first surgery during the study period was included in the analysis. The differences in clinical characteristics and outcomes between patients in the TAVR and SAVR groups were assessed using the t test for continuous variables and the chi-squared test for categorical variables. A survival model was initiated at the time of surgery and followed until death or last follow-up time up to 6 months after surgery. Survival was presented using the Kaplan-Meier plot and compared using the log-rank test. The multivariate logistic regression was performed to assess the association between intervention groups (TAVR versus SAVR) and AKI adjusting for variables with statistically significant difference in the univariate analysis. Adjusted odds ratios with 95% CIs were reported. A two-sided P value of ,0.05 was considered statistically significant. To further reduce the effect of the preoperative difference between the two groups, a matched cohort of patients treated with TAVR and SAVR was created using propensity score matching. 26 Propensity scores were estimated using logistic regression with TAVR as the dependent variable on the following covariates: STS risk score, eGFR, sex, body mass index, type of surgery (elective versus urgent/emergency), presence of anemia, history of diabetes mellitus, hypertension, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic lung disease, New York Heart Association class (classes 1 and 2 versus 3 and 4), preoperative use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, previous percutaneous cardiac intervention, previous coronary bypass grafting, previous aortic valve surgery, cardiac rhythm at surgery (normal versus other), and aortic valve insufficiency (none or trivial versus mild, moderate, or severe). Matching was performed in R statistical software (version 3.1.1; R, Vienna, Austria). 27 Patients in the TAVR and SAVR groups were matched on a 1:1 basis on the logit of the propensity score with a caliper width equal to 0.2 SD of the logit of the propensity score. 28 Covariate balance in the matched sample was assessed using the absolute standard difference, with an absolute standard difference of ,0.1 considered to denote a negligible imbalance in covariates between the TAVR and SAVR groups ( Figure  1) . 29, 30 Apart from propensity score matching, analyses were performed using JMP statistical software (version 10; SAS Institute, Inc., Cary, NC).
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